Author

A. N. Hata

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Biophysics· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Approach:statistical model· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:gene regulatory network inference· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

J. J. Lin· 3 shared C. Li· 2 shared K. Dionne· 2 shared L. V. Sequist· 2 shared N. Phan· 2 shared Z. Piotrowska· 2 shared A. Abbasi· 1 shared A. Acker· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. J. Lin

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

A cellular and spatial atlas of TP53-associated tissue remodeling in lung adenocarcinoma

W. Zhao, B. Kepecs, N. R. Mahadevan, A. Segerstolpe, J. L. Weirather, N. R. Besson, B. Giotti, B. Y. Soong, C. Li, S. Vigneau, M. Slyper, I. Wakiro, J. Jane-Valbuena, O. Ashenberg, A. Rotem, , A. M. Tsankov

This study constructs a multi-omic atlas of TP53-mutant lung adenocarcinoma tumors, revealing altered cellular identity, gene expression programs, and spatial interactions in the tumor microenvironment.

bioRxiv · Jun 28, 2023 · PreprintCancer Biology

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

K. Vaccaro, J. Allen, T. W. Whitfield, A. Maoz, S. Reeves, J. Velarde, D. Yang, N. Phan, G. W. Bell, A. N. Hata, K. Weiskopf

The paper identifies targeted therapies that enhance lung cancer vulnerability to macrophage attack when combined with anti-CD47 antibodies, showing synergy across multiple genetic mutations.

bioRxiv · Mar 3, 2023Cancer Biology

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

C. Li, M. U. Syed, A. Nimbalkar, Y. Shen, C. Fraser, Z. Inde, X. Qin, J. Ouyang, J. Kreuzer, S. E. Clark, G. E. Kelley, E. Hensley, A. Oh, M. Walcott, R. Morris, , A. N. Hata

This study shows LKB1 suppresses JNK-dependent stress signaling in KRAS-mutant lung cancers, revealing a therapy-induced vulnerability that could improve KRAS-targeted therapies.

bioRxiv · Sep 29, 2022 · PreprintCancer Biology

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A. Shiba-Ishii, T. W. Johnson, I. Dagogo-Jack, M. Mino-Kenudson, T. R. Johnson, P. Wei, S. L. Weinrich, M. A. McTigue, M. A. Walcott, L. Nguyen-Phuong, K. Dionne, A. Acker, L. Kiedrowski, A. Do, J. L. Peterson, , A. N. Hata

This study identifies lorlatinib-resistant ALK mutations and evaluates analogs to develop targeted therapies for compound resistance in ALK-positive lung cancer.

Nature Cancer · Jun 20, 2022Peer-reviewedCancer Biology

Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information

J. M. Heather, M. J. Spindler, M. Herrero Alonso, Y. I. Shui, D. G. Millar, D. S. Johnson, M. Cobbold, A. N. Hata

Stitchr generates full-length coding TCR sequences from V/J/CDR3 information, validated through synthesis and transduction in Jurkat cells, enabling efficient TCR engineering and analysis.

bioRxiv · Dec 20, 2021Immunology

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

H. Isozaki, A. Abbasi, N. Nikpour, A. Langenbucher, W. Su, M. Stanzione, H. Frisco-Cabanos, F. M. Siddiqui, N. Phan, P. Jalili, S. Oh, D. Timonina, S. Bilton, M. Gomez-Caraballo, H. L. Archibald, , A. N. Hata

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

bioRxiv · Jan 20, 2021Cancer Biology

Modeling Resistance and Recurrence Patterns of Combined Targeted- Chemoradiotherapy Predicts Benefit of Shorter Induction Period

D. M. McClatchy, H. Willers, A. N. Hata, Z. Piotrowska, L. V. Sequist, H. Paganetti, C. Grassberger

The paper develops a bio-mathematical model to simulate recurrence patterns in lung cancer under combined targeted therapy and CRT, showing that long induction periods may reduce the effectiveness of adjuvant therapy.

bioRxiv · Dec 2, 2019Biophysics